Association for the nuclear medicine sector applied to the development of radiotheranostics for the treatment of cancers or PROMETHE® (precision oncology medicine theranostics).
The goal is to improve public health by accelerating the R&D of radiotheranostic molecules. We have the following objectives:
- Federate and connect players in the field by:
- Communication and marketing
- Gather a structured local network bringing together all skills
- Promote public-private parterships at national and European level
- Organize conferences and seminars
- Participate to conferences / be member of societies, federations, associations…
- Develop the sector
- Stakeholder support for the production of medical isotopes
- Participation to the structuring of clinical services for better patient access
- Loobying for a proper MRT drug reimbursement
- Improving trainings
- Universities and private
- Communication to general public
- Information leaflets, videos… for patients and their families
- Science festival…
Company Details
- Address
- 18 Rue Jean Mazen, Dijon,21000,france
- Industry
- Public Health
- NAICS
-
Administration of Public Health Programs
- HQ
- Dijon
Promethe.eu Questions
Promethe.Eu's LinkedIn profile is https://fr.linkedin.com/company/promethe-eu
Promethe.Eu's industry is
Public Health
Promethe.Eu's top competitors are
Foundation For Nuclear Studies,
Oncodesign Precision Medicine - Opm,
Rotem Industries Ltd (Corporation),
Promethe,
Oncidium Foundation,
Prométhée 41 Cap Emploi 41,
Cnp Pharmacie (Conseil National Professionnel De La Pharmacie),
Nuclearone®,
Predict Ltd,
France Biotech.
Promethe.Eu's categories are Public Health
